Bioadaptives (BDPT) Gross Margin (2016 - 2026)

Bioadaptives has disclosed Gross Margin across 9 years of filings, most recently posting 74.59% for Q1 2026.

• Gross Margin for Q1 2026 came in at 74.59%, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was 69.81% (up 626.0% YoY), and the FY2025 annual result was 68.37%, up 3656.0% from the prior year.
• Gross Margin came in at 74.59% for Q1 2026 at Bioadaptives, up from 72.72% in the prior quarter.
• In the past five years, Gross Margin ranged from a high of 83.14% in Q3 2025 to a low of 25.85% in Q4 2022.
• The 5-year median for Gross Margin is 54.23% (2023), against an average of 51.24%.
• Across the five-year window, Gross Margin soared 2353 bps in 2023 and sank 3053 bps in 2025, its largest moves.
• Bioadaptives' Gross Margin stood at 25.85% in 2022, then surged by 45 bps to 37.48% in 2023, then jumped by 70 bps to 63.56% in 2024, then climbed by 14 bps to 72.72% in 2025, then rose by 3 bps to 74.59% in 2026.
• The last three Gross Margin figures came in at 74.59% (Q1 2026), 72.72% (Q4 2025), and 83.14% (Q3 2025), per Business Quant data.